Haier Biology: Shareholder Haichuangru intends to reduce its holding by no more than 0.85%.

Haier Biomedical announced that Qingdao Haichuang Rui Equity Investment Fund Center, a shareholder holding 10.14% of the shares, intends to reduce its holdings by no more than 2.69 million shares through centralized auction, accounting for 0.85% of the total share capital of the company, due to capital needs. The reduction period is from March 3, 2026 to June 2, 2026; it currently holds 32.1037 million shares, all of which were acquired before the IPO. As of the announcement disclosure date, the actual controller and the concerted actors collectively hold 141 million shares, accounting for 44.67% of the total, and have not reduced their shareholding in the company since listing. The reduction plan will not result in a change in control.